Leadership

Thomas A. Bologna is an experienced Chairman, President and Chief Executive Officer in leading public, venture and private equity-backed diagnostic, pharmaceutical, device and clinical laboratory testing healthcare companies including turnarounds and start-ups, many of which he sold and/or took public.

Mr. Bologna was Chairman of the Board and Chief Executive Officer of Response Genetics, Inc., a clinical laboratory company, President and Chief Executive Officer of Orchid Cellmark, Inc., a leading DNA testing services company with operations in the United States and Europe, President and Chief Executive Officer of Quorex Pharmaceuticals, Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a company that developed and commercialized products for the therapeutic management of osteoporosis and Chairman of the Board, President and Chief Executive Officer of Gen-Probe, Incorporated, a highly successful molecular diagnostics company.

Mr. Bologna also held senior-level positions at highly profitable healthcare divisions and subsidiaries of Fortune 500 companies including President of the Becton Dickinson Diagnostic Instrument Systems Division. He was also a founder and member of the Sponsoring Committee of the venture capital firm, Mission Ventures.

Mr. Bologna received his B.S. from the New York University School of Engineering and Science and his M.B.A. from the New York University Graduate School of Business Administration.

Roger O'Sullivan is a corporate attorney with extensive experience providing day-to-day counsel to senior management and boards of directors regarding corporate and commercial transactions, regulatory compliance, dispute resolution, corporate governance, and development, protection, and commercialization of intellectual property.

Mr. O'Sullivan spent over ten years as General Counsel, Corporate Secretary and Chief Privacy Officer of a publicly traded cognitive science company that commercializes cognitive tests for use in clinical trials, academic research and healthcare. He also served as Chair of the company's Security and Privacy Committee driving development and providing oversight of its HIPAA and GDPR programs.

Mr. O'Sullivan is currently advisor to a neuroscience technology company that uses speech and language biometrics to enhance decision making in clinical trials and a member of the American Health Law Association and the Association of Corporate Counsel.

Mr. Balog has over 30 years of investment-related experience. From 1983 to 2002, Mr. Balog was an equity analyst and research executive. He was recognized 5 years running by the Institutional Investor magazine's All-American research poll for his work on the electronics industry while at Prudential Bache and Shearson Lehman Brothers.

In 1990, he moved into research management at Lehman Brothers. In 1995, he joined Furman Selz as a Director of Research and drove the rapid buildup of the firm's research department prior to the firm's sale to ING Barings. After working on an entrepreneurial endeavor, Mr. Balog joined Merrill Lynch in 2000 to lead the research efforts in the global technology industry. After leaving Merrill Lynch, in 2002, Mr. Balog joined Cedar Creek Management, a value-oriented, long/short investment partnership based in Summit, New Jersey, where he served as a partner through the partnership's close in 2009. From 2010 to 2011, Mr. Balog was Chief Investment Officer at Beacon Trust Company.

After leaving Beacon Trust, Mr. Balog has focused on making private equity and venture capital investments. Mr. Balog holds a BS in Mechanical Engineering from Bucknell University and an MBA in Finance from the University of Pennsylvania's Wharton School. Mr. Balog is currently active or has served on various non-profit boards, including the NY Society of Security Analysts, the Citizens Campaign (treasurer), Covenant House, Kemmerer Library, Harding Township (president, treasurer and investment committee chair), Harding Township Civic Association and St. Joseph's High School, Metuchen (trustee and foundation).

On the for-profit side, Mr. Balog was a trustee of Lehman Brothers Employee Pension Fund and was on the board of Furman Selz, LLC. Mr. Balog is currently a member of the Audit Committee, Nominating and Governance Committee, Compliance Committee, and Valuation Committee (Chair — effective May 4, 2016) of the Trust's Board of Trustees.

Michael D. Bacon represents Bhansali SFO DMCC, a single-family office based out of Dubai, U.A.E. The firm takes a multi-strategy approach to long-term asset appreciation and holds a global investment portfolio of public equities, private equity, real estate, and fixed income instruments.  Its private equity portfolio is focused on the technology, financial services, and healthcare sectors.

Mr. Bacon has extensive investing and operating experience in a variety of industry areas including media, technology, aerospace/defense, healthcare and telecommunications as both an investor and an operator.  Mr. Bacon was part of the sponsor group, and later served as Executive Vice President and Chief Financial Officer, of Sheridan Square Entertainment, Inc., one of the largest independent music production and distribution companies.  As CFO, Mr. Bacon oversaw all the Company's financial and business development operations, including M&A, corporate finance, treasury, and investor/lender relations until its sale to Entertainment One (ETO:LN) in 2007.  

Prior to Sheridan Square, Mr. Bacon was an executive at Raytheon Commercial Ventures, placing investment capital and leveraging Raytheon Corporation's proprietary technologies to build commercial businesses.  Before Raytheon, Mr. Bacon was a corporate executive at Artisan Entertainment, Inc., a leveraged roll-up of film and video distribution assets and a portfolio company of Bain Capital. At Artisan, Mr. Bacon was involved in all aspects of the company's activities including M&A, corporate finance, treasury and operations. Artisan became the largest independent filmed entertainment production and distribution company until its sale to Lion's Gate Entertainment, Inc. (NYSE: LGF.A) in 2003. Prior to his time at Artisan, Mr. Bacon was a corporate strategy consultant for A.T. Kearney, Inc. in San Francisco, CA where he advised Fortune 500 clients in a variety of industries on acquisitions, growth strategy and new market penetration.

Mr. Bacon received his B.A. in Economics from the University of Notre Dame and his M.B.A. in Finance from the Wharton School at the University of Pennsylvania.

Mr. Jahns is the Managing Director of Galen Partners. With over 25 years of experience in building healthcare companies, he is passionate about working collaboratively with innovative management teams to create novel solutions that improve healthcare quality and safety for patients while reducing the cost of delivery to the system. With experience in over 70 growth equity investments, Mr. Jahns has developed substantial expertise and leadership in working with entrepreneurs to build market-leading healthcare companies in the areas of technology-enabled services, medical devices, medical robotics, diagnostics, consumer-driven healthcare, telemedicine, clinical decision support, and health information technology and SaaS solutions. The following are market-leading healthcare companies in which Mr. Jahns has taken a leadership role: CBL Path, Chamberlin Edmonds, Eduneering, Encore Medical, InTouch Health, lifeIMAGE, MedAssets, MiniMed, Ocular Sciences, PeriGen, Pyxis, Sharecare, Stericycle, Unisyn Medical Technologies and SonaCare.

Prior to joining Galen in 1993, Mr. Jahns was an investment banker and financial advisor to healthcare companies. He worked in the Corporate Finance Department at Smith Barney, Inc. in New York, specializing in public offerings and mergers and acquisitions, as well as public debt financings. As an investment banker and venture capitalist, Mr. Jahns has worked on more than 20 initial public offerings, including 11 IPOs of Galen's portfolio companies. Additionally, he has extensive M&A experience, including 19 sales to financial and strategic buyers of Galen's portfolio companies.Mr. Jahns has served on numerous public and private company boards of directors. He is a member of the Board of Directors and the Quality and Clinical Affairs Committee of Stamford Health System, Inc. He is a frequent speaker at various healthcare industry conferences on healthcare market trends and the healthcare technology-enabled outsourcing industry. He is also a guest lecturer at the Kellogg School of Management and mentors to the Kellogg Venture Lab program. He also serves on several non-profit boards of directors for various community and philanthropic corporations.Mr. Jahns earned an M.B.A. from the Northwestern University, Kellogg School of Management, where he specialized in Health Services Management. He earned his B.A. in political science and economics from Colgate University, where he graduated Phi Beta Kappa.

Mr. John Watts has more than 30 years of experience in building, growing and leading large health plan organizations. His experience includes leading successful organizations to higher growth targets, through turnaround situations, and building successful new ventures. John also has significant experience in managing P&L for large enterprises.

John spent 12 years at WellPoint, the nation's largest insurer with approximately 35 million members, where he held numerous executive positions, including chief executive and president of Blue Cross Blue Shield of Georgia and president and CEO of National Accounts. In his most recent position as president and CEO of WellPoint's Commercial and Consumer Business, he directed a $50 billion division that encompassed 14 Blue Cross Blue Shield plans.

John is currently on the board of a number of healthcare-related companies including, Blue Cross and Blue Shield of Minnesota, Paradigm Outcomes and Zenith American. In addition, he facilitates roundtable discussions with CEO's from across the healthcare industry as a Managing Director of the Center for Corporate Innovation.

He earned his BA in English from the University of California, Los Angeles (UCLA).

Edward Yom joined CDx Diagnostics in 2022 as a senior executive in technology bringing over 28 years of professional experience. Edward is a dynamic & strategic executive driving results by mobilizing teams that execute, strategize, build, and operationalize global technology & digital strategies.  Edward has specialized in various disciplines including IT operations, engineering & architecture, information security, IT infrastructure, project portfolio management, service delivery, business relationship, business technology & digital transformation, and cultural & talent development.  

Edward has held multiple leadership positions in financial services, manufacturing, consumer goods, high-tech, pharmaceutical, medical devices & diagnostics, health services, education, and non-profit organizations.  Edward has a bachelor’s degree of science in Organizational Psychology from the University of Illinois at Urbana-Champaign, a mini-MBA from the Rutgers Business School, along with numerous professional certifications from Northwestern, Yale, and Stanford.  Edward also has Master Certifications in ITIL and Scrum.

Dr. Hoffman is the Director of Research at CDx Diagnostics responsible for developing and supervising clinical studies. She has been at CDx for 5 years.

Robert received an undergraduate degree in Physics from Fordham University, a Bachelor's and Master's Degree in Electrical Engineering from Columbia University, in a relatively short time span of 6 years. In 1988, he worked as a Research Associate with Dr. Leopold Koss at Montefiore Hospital to develop classifiers to recognize cancer cells in voided urine using image processing and multivariable statistical analysis. In 1990, he joined Neuromedical Systems, a startup company, to develop a premier application to sort cancer cells in cervical pap smears using neural networks. He was instrumental in submitting a PMA to the FDA as a medical device. Its success lead to a successful IPO of 30 million dollars.

For a year, he worked for TriPath Imaging to develop a virtual microscope, a universal plug-in to work with a multitude of microscopes. Subsequently, he worked for Physiome Sciences to develop computerized physiological models of human and animal cells, to understand and accelerate the development of pharmaceutical drugs. Starting in 2003, at OralCDx, Robert developed the next generation high-resolution scanner system and developed specific technologies to further increase both the image quality and overall accuracy and sensitivity of the system to analyze thick brush biopsy samples.

Dr. Frank Fromowitz has over 35 years of experience as an anatomic pathologist in academic, community hospital, and private laboratory settings, including work in the pathology of the gastrointestinal tract. He trained in Anatomic Pathology at Yale University School of Medicine, held full-time academic appointments at the state universities of New York and New Jersey, and published over 50 articles in peer-reviewed journals, including the New England Journal of Medicine and Cancer. Dr. Fromowitz has worked with such noted pathologists as Drs. Charles Carrington, Leo Koss, and Lauren Ackerman, has taught medical students and residents at several institutions and was nominated for the Golden Apple Teaching Award at the New Jersey Medical School.

Dr. Schreiber is a board-certified anatomic and clinical pathologist with experience in both commercial laboratories as well as academic hospitals. He has been an integral part of the CDx diagnostics team since 2013.

Dr. Schreiber completed his medical school at the Medical College of Wisconsin. His residency training for Anatomic and Clinical Pathology was at SUNY Stony Brook, where he was Chief Resident.  He completed a Post-Doctoral Fellowship at NY-Presbyterian Hospital Columbia University for Surgical Pathology and GI Pathology.